Get the Stockscreener App
2.28
1.79%
0.04
After Hours:
2.26
-0.02
-0.88%
BiomX Inc stock is traded at $2.28, with a volume of 59,799.
It is up +1.79% in the last 24 hours and down -6.56% over the past month.
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$2.24
Open:
$2.18
24h Volume:
59,799
Relative Volume:
0.73
Market Cap:
$3.48M
Revenue:
-
Net Income/Loss:
$-23.14M
P/E Ratio:
-2.2505
EPS:
-1.0131
Net Cash Flow:
$-29.23M
1W Performance:
+6.54%
1M Performance:
-6.56%
6M Performance:
-71.43%
1Y Performance:
-83.77%
1-Day Range:
$2.07
$2.28
1-Week Range:
$2.0662
$2.28
52-Week Range:
$1.5004
$22.06
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Compare PHGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHGE
BiomX Inc
|
2.28 | 3.42M | 0 | -23.14M | -29.23M | -1.0131 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
BiomX Inc Stock (PHGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
How interest rate cuts could boost BiomX Inc. stockWeekly Trading Summary & Community Consensus Trade Alerts - ulpravda.ru
Is BiomX Inc. stock oversold or undervaluedCPI Data & Technical Entry and Exit Alerts - ulpravda.ru
Is BiomX Inc. stock dividend yield sustainableMarket Weekly Review & High Conviction Buy Zone Alerts - ulpravda.ru
Is BiomX Inc. stock resilient to inflationNew Guidance & AI Based Buy and Sell Signals - ulpravda.ru
Is BiomX Inc. stock ready for breakoutProtective Put Strategies & Free Dynamic Profit Opportunities - ulpravda.ru
BiomX announces new preferred stock financing and warrants - MSN
Chart Watch: Will BiomX Inc stock sustain uptrend momentum2025 Key Lessons & Reliable Entry Point Trade Alerts - moha.gov.vn
Growth Report: Is BiomX Inc stock recession proofJuly 2025 EndofMonth & High Win Rate Trade Tips - moha.gov.vn
BiomX announces $3M private placement - MSN
All you need to know about BiomX (PHGE) rating upgrade to buy - MSN
BiomX Announces $3.0 Million Private Placement - The Globe and Mail
BiomX Announces New Preferred Stock Financing and Warrants - TipRanks
BiomX Signs Multiple Material Agreements - TradingView — Track All Markets
All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy - Yahoo Finance
BiomX (PHGE) Secures $3M Through Private Investment Initiative - GuruFocus
RSI Suggests Rebound May Be Near in Shree Cement LimitedCash Flow Trends & Free Dynamic Profit Opportunities - earlytimes.in
Is BiomX Inc. stock a buy before product launchesJobs Report & Target Return Focused Stock Picks - DonanımHaber
Is BiomX Inc. stock recession proofEarnings Growth Report & Consistent Growth Stock Picks - DonanımHaber
Will BiomX Inc. stock outperform foreign stocksJuly 2025 Reactions & High Win Rate Trade Alerts - DonanımHaber
BiomX (NYSEAMERICAN:PHGE) Shares Up 9.9% – Still a Buy? - Defense World
What risks investors should watch in BiomX Inc. stockPortfolio Risk Report & AI Enhanced Trading Alerts - DonanımHaber
Market Rankings: Can BiomX Inc. stock reach $100 price targetJuly 2025 EndofMonth & Safe Entry Zone Tips - Улправда
BiomX collapses into court proceedings after clinical trial fails - CTech
BIOMX INCDECISION FOLLOWS SAFETY REVIEW BY INDEPENDENT DMC - 富途牛牛
BiomX Discontinues Study and Files for Insolvency - TipRanks
BiomX Inc. Discontinues Phase 2b Study and Initiates Insolvency Proceedings - TradingView — Track All Markets
BiomX (NYSE: PHGE) subsidiary seeks insolvency as Phase 2b study ends, BX011 program retained - Stock Titan
BiomX Discontinues Phase 2b Trial for BX004 - The Globe and Mail
Earnings Beat: Is BiomX Inc stock oversold or undervaluedJuly 2025 Market Mood & Free Technical Confirmation Trade Alerts - moha.gov.vn
Healthy Upside Potential: BiomX Inc (PHGE) - setenews.com
BiomX Halts Phase 2b Trial Of BX004 In Cystic Fibrosis On High Rates Of Adverse Events - Nasdaq
Stocks Tumble As Bad News Hits Biotech And Energy Sectors - Finimize
BiomX Discontinues Phase 2b Clinical Trial for BX004 - TradingView — Track All Markets
BiomX (PHGE) Halts Phase 2b Trial and Implements Cost-Saving Str - GuruFocus
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review - The Manila Times
BiomX announces discontinuation of phase 2b Bx004 trial following internal review - marketscreener.com
BiomX (PHGE) Price Target Increased by 964.52% to 168.30 - Nasdaq
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
BiomX (PHGE) Stock Analysis Report | Financials & Insights - Benzinga
Why BiomX Inc. stock could be top winner2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
How BiomX Inc. stock performs in high volatility marketsJuly 2025 Update & Daily Price Action Insights - Newser
BiomX Is Targeting the Infection Threat Returning to Modern WarAnd the Military Is Paying Attention (NYSE: PHGE) - markets.businessinsider.com
How BiomX Inc. stock reacts to Fed tighteningJuly 2025 Update & AI Forecasted Entry/Exit Points - Newser
How BiomX Inc. stock compares with tech leadersJuly 2025 Review & Technical Pattern Alert System - Newser
How forex fluctuations impact BiomX Inc. stockWeekly Stock Recap & High Yield Equity Trading Tips - Newser
Is BiomX Inc. stock ideal for retirement investorsMarket Growth Report & Comprehensive Market Scan Reports - Newser
How BiomX Inc. stock behaves in tightening cyclesAnalyst Downgrade & Safe Entry Trade Signal Reports - Newser
BiomX Inc Stock (PHGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):